Pierre-Yves Bochud

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


162 publications

In press | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 1995 | 1994 |
 
BK Polyomavirus (BKPyV) Serotype-Specific Antibody Responses in Blood Donors and Kidney Transplant Recipients with and without new-onset BKPyV-DNAemia: A Swiss Transplant Cohort Study.
Hillenbrand C.A., Bani D.A., Follonier O., Kaur A., Weissbach F.H., Wernli M., Wilhelm M., Leuzinger K., Binet I., Bochud P.Y. et al. American journal of transplantation. Peer-reviewed.
 
Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Halfon M., Taffé P., Bucher C., Haidar F., Huynh-do U., Mani L.Y., Schachtner T., Wehmeier C., Venetz J.P., Pascual M. et al., 2025/01. Kidney international reports, 10 (1) pp. 75-86. Peer-reviewed.
Herpes simplex encephalitis due to a mutation in an E3 ubiquitin ligase.
Bibert S., Quinodoz M., Perriot S., Krebs F.S., Jan M., Malta R.C., Collinet E., Canales M., Mathias A., Faignart N. et al., 2024/05/10. Nature communications, 15 (1) p. 3969. Peer-reviewed.
Antifungal Treatment Duration in Hematology Patients With Invasive Mold Infections: A Real-life Update.
Portillo V., Ragozzino S., Stavropoulou E., El-Khoury C., Bochud P.Y., Lamoth F., Khanna N., Neofytos D., 2024/05. Open forum infectious diseases, 11 (5) pp. ofae201. Peer-reviewed.
Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).
Couchepin J., Reinhold I., Kronig I., Guidi M., Buclin T., Schreiber P.W., Neofytos D., Lamoth F., Fungal Infection Network of Switzerland (FUNGINOS), 2024/05. Open forum infectious diseases, 11 (5) pp. ofae223. Peer-reviewed.
Investigations of an increased incidence of non-Aspergillus invasive mould infections in an onco-haematology unit.
Stavropoulou E., Huguenin A., Caruana G., Opota O., Perrottet N., Blanc D.S., Grandbastien B., Senn L., Bochud P.Y., Lamoth F., 2024/03/26. Swiss medical weekly, 154 p. 3730. Peer-reviewed.
A Functional Polymorphism in IL-1B Is Associated With Immune Reconstitution Inflammatory Syndrome of Chronic Disseminated Candidiasis.
Rammaert B., Bochud P.Y., Brunel A.S., Wojtowicz A., Candon S., Gallego Hernanz M.P., Lortholary O., 2023/03. Open forum infectious diseases, 10 (3) pp. ofad078. Peer-reviewed.
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Maertens J., Lodewyck T., Donnelly J.P., Chantepie S., Robin C., Blijlevens N., Turlure P., Selleslag D., Baron F., Aoun M. et al., 2023/02/18. Clinical infectious diseases, 76 (4) pp. 674-682. Peer-reviewed.
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative.
Butler-Laporte G., Povysil G., Kosmicki J.A., Cirulli E.T., Drivas T., Furini S., Saad C., Schmidt A., Olszewski P., Korotko U. et al., 2022/11. PLoS genetics, 18 (11) pp. e1010367. Peer-reviewed.
 
High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
Tschopp J., Brunel A.S., Spertini O., Croxatto A., Lamoth F., Bochud P.Y., 2022/08/25. Clinical infectious diseases, 75 (2) pp. 330-333. Peer-reviewed.
Κey Role of Early Source Control in Candidemic Patients With Sepsis or Septic Shock.
Papadimitriou-Olivgeris M., Battistolo J., Poissy J., Coste A., Bochud P.Y., Calandra T., Senn L., Lamoth F., 2022/08. Open forum infectious diseases, 9 (8) pp. ofac383. Peer-reviewed.
Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19.
Kritikos A., Gabellon S., Pagani J.L., Monti M., Bochud P.Y., Manuel O., Coste A., Greub G., Perreau M., Pantaleo G. et al., 2022/05/18. Viruses, 14 (5) p. 1089. Peer-reviewed.
Tularémie pulmonaire : un diagnostic à ne pas manquer [Pulmonary tularemia : a diagnosis not to be missed]
Uriel Valladares P., Opota O., Beigelman-Aubry C., Bochud P.Y., Lamoth F., 2022/04/13. Revue medicale suisse, 18 (777) pp. 707-711. Peer-reviewed.
Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia.
Albasanz-Puig A., Durà-Miralles X., Laporte-Amargós J., Mussetti A., Ruiz-Camps I., Puerta-Alcalde P., Abdala E., Oltolini C., Akova M., Montejo J.M. et al., 2022/03/29. Microorganisms, 10 (4) p. 733. Peer-reviewed.
Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections.
Roth R.S., Masouridi-Levrat S., Giannotti F., Mamez A.C., Glambedakis E., Lamoth F., Bochud P.Y., Erard V., Emonet S., Van Delden C. et al., 2022/02. Mycoses, 65 (2) pp. 199-210. Peer-reviewed.
Cohort profile: The Swiss Transplant Cohort Study (STCS): A nationwide longitudinal cohort study of all solid organ recipients in Switzerland.
Stampf S., Mueller N.J., van Delden C., Pascual M., Manuel O., Banz V., Binet I., De Geest S., Bochud P.Y., Leichtle A. et al., 2021/12/15. BMJ open, 11 (12) pp. e051176. Peer-reviewed.
Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital.
Battistolo J., Glampedakis E., Damonti L., Poissy J., Grandbastien B., Kalbermatter L., Pagani J.L., Eggimann P., Bochud P.Y., Calandra T. et al., 2021/12. Mycoses, 64 (12) pp. 1512-1520. Peer-reviewed.
Mapping the human genetic architecture of COVID-19.
COVID-19 Host Genetics Initiative, Niemi M.E.K, 2021/12. Nature, 600 (7889) pp. 472-477. Peer-reviewed.
The EHA Research Roadmap: Infections in Hematology.
Cordonnier C., Ljungman P., Cesaro S., Hirsch H.H., Maschmeyer G., von Lilienfeld-Toal M., Vehreschild M., Mikulska M., Emonts M., Gennery A.R. et al., 2021/12. HemaSphere, 5 (12) pp. e662. Peer-reviewed.
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.
Adam K.M., Osthoff M., Lamoth F., Conen A., Erard V., Boggian K., Schreiber P.W., Zimmerli S., Bochud P.Y., Neofytos D. et al., 2021/10. Open forum infectious diseases, 8 (10) pp. ofab471. Peer-reviewed.
Postmortem Cardiopulmonary Pathology in Patients with COVID-19 Infection: Single-Center Report of 12 Autopsies from Lausanne, Switzerland.
Berezowska S., Lefort K., Ioannidou K., Ndiaye D.R., Maison D., Petrovas C., Rotman S., Piazzon N., Milowich D., Sala N. et al., 2021/07/28. Diagnostics, 11 (8) p. 1357. Peer-reviewed.
Invasive Hormographiella aspergillata infection in patients with acute myeloid leukemia: Report of two cases successfully treated and review of the literature.
Tschopp J., Perentes J.Y., Beigelman-Aubry C., Berezowska S., Lovis A., Spertini O., Bochud P.Y., Lamoth F., 2021/06. Medical mycology case reports, 32 pp. 68-72. Peer-reviewed.
 
Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study.
Glampedakis E., Cassaing S., Fekkar A., Dannaoui E., Bougnoux M.E., Bretagne S., Neofytos D., Schreiber P.W., Hennequin C., Morio F. et al., 2021/04/26. Clinical infectious diseases, 72 (8) pp. 1379-1385. Peer-reviewed.
Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients.
Bibert S., Guex N., Lourenco J., Brahier T., Papadimitriou-Olivgeris M., Damonti L., Manuel O., Liechti R., Götz L., Tschopp J. et al., 2021. Frontiers in immunology, 12 p. 666163. Peer-reviewed.
 
High prevalence of peribronchial focal lesions of airway invasive aspergillosis in hematological cancer patients with prolonged neutropenia.
Casutt A., Couchepin J., Brunel A.S., Lovis A., Bochud P.Y., Keller N., Lamoth F., Beigelman-Aubry C., 2020/09/01. The British journal of radiology, 93 (1113) p. 20190693. Peer-reviewed.
Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature.
Stavropoulou E., Coste A.T., Beigelman-Aubry C., Letovanec I., Spertini O., Lovis A., Krueger T., Burger R., Bochud P.Y., Lamoth F., 2020/07/22. BMC infectious diseases, 20 (1) p. 527. Peer-reviewed.
 
Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial.
von Dach E., Albrich W.C., Brunel A.S., Prendki V., Cuvelier C., Flury D., Gayet-Ageron A., Huttner B., Kohler P., Lemmenmeier E. et al., 2020/06/02. JAMA, 323 (21) pp. 2160-2169. Peer-reviewed.
 
Polymorphisms of SOCS-1 Are Associated With a Rapid HIV Progression Rate.
Hersberger M., Schlaepfer E., Buehler M., Bochud P.Y., Vernazza P., Marti-Jaun J., Nemeth J., Zwahlen M., Schmidlin K., Speck R.F. et al., 2020/06/01. Journal of acquired immune deficiency syndromes, 84 (2) pp. 189-195. Peer-reviewed.
 
Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis
Kritikos Antonios, Poissy Julien, Croxatto Antony, Bochud Pierre-Yves, Pagani Jean-Luc, Lamoth Frederic, 2020/04/01. Journal of Clinical Microbiology, 58 (6) pp. e01996-19. Peer-reviewed.
Risk factors for candidemia: a prospective matched case-control study.
Poissy J., Damonti L., Bignon A., Khanna N., Von Kietzell M., Boggian K., Neofytos D., Vuotto F., Coiteux V., Artru F. et al., 2020/03/18. Critical care, 24 (1) p. 109. Peer-reviewed.
Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis.
Lamoth F., Clancy C.J., Tissot F., Squires K., Eggimann P., Flückiger U., Siegemund M., Orasch C., Zimmerli S., Calandra T. et al., 2020/03. Open forum infectious diseases, 7 (3) pp. ofaa075. Peer-reviewed.
 
Correction for Cornu et al., "Evaluation of Mass Spectrometry-Based Detection of Panfungal Serum Disaccharide for Diagnosis of Invasive Fungal Infections: Results from a Collaborative Study Involving Six European Clinical Centers".
Cornu M., Sendid B., Mery A., François N., Mikulska M., Letscher-Bru V., De Carolis E., Damonti L., Titecat M., Bochud P.Y. et al., 2019/12/23. Journal of clinical microbiology, 58 (1). Peer-reviewed.
Herpes simplex encephalitis in adult patients with MASP-2 deficiency.
Bibert S., Piret J., Quinodoz M., Collinet E., Zoete V., Michielin O., Menasria R., Meylan P., Bihl T., Erard V. et al., 2019/12. PLoS pathogens, 15 (12) pp. e1008168. Peer-reviewed.
 
rs34567942 a Novel Susceptibility Single Nucleotide Polymorphism for Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients.
Kuzmanov A., Qi W., Stenz N., Bochud P.Y., Kutalik Z., Wojtowicz A., Hofbauer G., 2019/12/01. Acta dermato-venereologica, 99 (13) pp. 1303-1304. Peer-reviewed.
IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.
Wójtowicz A., Bibert S., Taffé P., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Osthoff M., Cavassini M., Bochud P.Y. et al., 2019/09. AIDS, 33 (11) pp. 1719-1727. Peer-reviewed.
Evaluation of Mass Spectrometry-Based Detection of Panfungal Serum Disaccharide for Diagnosis of Invasive Fungal Infections: Results from a Collaborative Study Involving Six European Clinical Centers.
Cornu M., Sendid B., Mery A., François N., Mikulska M., Letscher-Bru V., De Carolis E., Damonti L., Titecat M., Bochud P.Y. et al., 2019/05. Journal of clinical microbiology, 57 (5). Peer-reviewed.
Infectiologie sur mesure - 1.Immunogénétique des maladies infectieuses : premiers pas [Customised infectiology - Immunogenetics]
Neofytos D., Bibert S., Bochud P.Y., 2019/04/10. Revue medicale suisse, 15 (646) pp. 766-770. Peer-reviewed.
 
Infectiologie sur mesure - 2. Phagothérapie : de la théorie à l’évidence clinique [Customised infectiology - Phage therapy: from theory to clinical evidence]
Desgranges F., Bochud P.Y., Resch G., 2019/04/10. Revue medicale suisse, 15 (646) pp. 771-775. Peer-reviewed.
La personnalisation : une approche ancrée dans les gènes de l’infectiologie.
Bochud P.Y., Kaiser L., Calandra T., 2019/04/10. Revue medicale suisse, 15 (646) pp. 763-764. Peer-reviewed.
 
Genetic and clinic predictors of new onset diabetes mellitus after transplantation.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Mueller N.J., Binet I., Van Delden C., Steiger J., Mohacsi P. et al., 2019/02. The pharmacogenomics journal, 19 (1) pp. 53-64. Peer-reviewed.
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
Quteineh L., Wójtowicz A., Bochud P.Y., Crettol S., Vandenberghe F., Venetz J.P., Manuel O., Golshayan D., Lehmann R., Mueller N.J. et al., 2019/01. American journal of transplantation, 19 (1) pp. 238-246. Peer-reviewed.
Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing.
About F., Bibert S., Jouanguy E., Nalpas B., Lorenzo L., Rattina V., Zarhrate M., Hanein S., Munteanu M., Müllhaupt B. et al., 2019. Frontiers in genetics, 10 p. 1024. Peer-reviewed.
 
Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.
Bibert S., Wójtowicz A., Taffé P., Tarr P.E., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Kaiser L., Osthoff M. et al., 2018/11/28. AIDS, 32 (18) pp. 2759-2765. Peer-reviewed.
 
Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A., Neofytos D., Khanna N., Schreiber P.W., Boggian K., Bille J., Schrenzel J., Mühlethaler K., Zbinden R., Bruderer T. et al., 2018/11. Clinical microbiology and infection, 24 (11) pp. 1214.e1-1214.e4. Peer-reviewed.
 
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.
Brunel A.S., Wójtowicz A., Lamoth F., Spertini O., Neofytos D., Calandra T., Marchetti O., Bochud P.Y., 2018/11. Haematologica, 103 (11) pp. e527-e530. Peer-reviewed.
 
Role of bi-weekly serum galactomannan screening for the diagnosis of invasive aspergillosis in haematological cancer patients.
Couchepin J., Brunel A.S., Jaton K., Meylan P., Bochud P.Y., Lamoth F., 2018/06. Mycoses, 61 (6) pp. 350-354. Peer-reviewed.
 
Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study.
Orasch C., Mertz D., Garbino J., van Delden C., Emonet S., Schrenzel J., Zimmerli S., Damonti L., Mühlethaler K., Imhof A. et al., 2018/05. The Journal of infection, 76 (5) pp. 489-495. Peer-reviewed.
 
LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions.
Yu K., Davidson C.L., Wójtowicz A., Lisboa L., Wang T., Airo A.M., Villard J., Buratto J., Sandalova T., Achour A. et al., 2018/04/02. The Journal of clinical investigation, 128 (4) pp. 1523-1537. Peer-reviewed.
 
Correction to: Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.
Damonti L., Erard V., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Imhof A., Zbinden R., Fehr J., Boggian K. et al., 2018/03..
 
A systematic review and meta-analysis of HCV clearance.
Gauthiez E., Habfast-Robertson I., Rüeger S., Kutalik Z., Aubert V., Berg T., Cerny A., Gorgievski M., George J., Heim M.H. et al., 2017/10. Liver international, 37 (10) pp. 1431-1445. Peer-reviewed.
 
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.
Fischer J., Weber ANR, Böhm S., Dickhöfer S., El Maadidi S., Deichsel D., Knop V., Klinker H., Möller B., Rasenack J. et al., 2017/10. Gut, 66 (10) pp. 1829-1837. Peer-reviewed.
BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.
Oussalah A., Avogbe P.H., Guyot E., Chery C., Guéant-Rodriguez R.M., Ganne-Carrié N., Cobat A., Moradpour D., Nalpas B., Negro F. et al., 2017/09/08. Oncotarget, 8 (38) pp. 62842-62857. Peer-reviewed.
PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia.
Huttner A., Albrich W.C., Bochud P.Y., Gayet-Ageron A., Rossel A., Dach E.V., Harbarth S., Kaiser L., 2017/07/13. BMJ open, 7 (7) pp. e017996. Peer-reviewed.
 
Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.
Damonti L., Erard V., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Imhof A., Zbinden R., Fehr J., Boggian K. et al., 2017/06. Intensive care medicine, 43 (6) pp. 935-939. Peer-reviewed.
 
Human MicroRNA Responses Predict Cytomegalovirus Replication Following Solid Organ Transplantation.
Han S.H., Kumar D., Ferreira V.H., Egli A., Hirsch H.H., Weisser M., Garzoni C., van Delden C., Bochud P.Y., Manuel O. et al., 2017/02/15. The Journal of infectious diseases, 215 (4) pp. 537-546. Peer-reviewed.
Bacillus cereus bacteraemia: comparison between haematologic and nonhaematologic patients.
Tusgul S., Prod'hom G., Senn L., Meuli R., Bochud P.Y., Giulieri S.G., 2017/01. New microbes and new infections, 15 pp. 65-71. Peer-reviewed.
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
Quteineh L., Bochud P.Y., Golshayan D., Crettol S., Venetz J.P., Manuel O., Kutalik Z., Treyer A., Lehmann R., Mueller N.J. et al., 2017/01. The pharmacogenomics journal, 17 (1) pp. 69-75. Peer-reviewed.
Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms.
Bibert S., Bratschi M.W., Aboagye S.Y., Collinet E., Scherr N., Yeboah-Manu D., Beuret C., Pluschke G., Bochud P.Y., 2017. Frontiers in microbiology, 8 p. 1903. Peer-reviewed.
 
Risk stratification and immunogenetic risk for infections following stem cell transplantation.
Wójtowicz A., Bochud P.Y., 2016/11/16. Virulence, 7 (8) pp. 917-929. Peer-reviewed.
 
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
Ulveling D., Le Clerc S., Cobat A., Labib T., Noirel J., Laville V., Coulonges C., Carpentier W., Nalpas B., Heim M.H. et al., 2016/11. Hepatology, 64 (5) pp. 1462-1472. Peer-reviewed.
 
A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantation.
Buhler S., Giostra E., Gbame C., de Rham C., Mullhaupt B., Dufour J.F., Majno P., Negro F., Bochud P.Y., Villard J. et al., 2016/09. Liver international, 36 (9) pp. 1331-1339. Peer-reviewed.
 
Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation.
Golshayan D., Wójtowicz A., Bibert S., Pyndiah N., Manuel O., Binet I., Buhler L.H., Huynh-Do U., Mueller T., Steiger J. et al., 2016/04. Kidney international, 89 (4) pp. 927-938. Peer-reviewed.
 
Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland.
Osthoff M., Wojtowicz A., Tissot F., Jørgensen C., Thiel S., Zimmerli S., Marchetti O., Khanna N., Bochud P.Y., Trendelenburg M. et al., 2016. Journal of Infection, 72 (3) pp. 377-385. Peer-reviewed.
Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis.
Savva A., Brouwer M.C., Roger T., Valls Serón M., Le Roy D., Ferwerda B., van der Ende A., Bochud P.Y., van de Beek D., Calandra T., 2016. Proceedings of the National Academy of Sciences of the United States of America, 113 (13) pp. 3597-3602. Peer-reviewed.
 
Host - hepatitis C viral interactions: The role of genetics.
Heim M.H., Bochud P.Y., George J., 2016. Journal of Hepatology, 65 (1 Suppl) pp. S22-S32. Peer-reviewed.
Host response to fungal infections - how immunology and host genetics could help to identify and treat patients at risk.
Khanna N., Stuehler C., Lünemann A., Wójtowicz A., Bochud P.Y., Leibundgut-Landmann S., 2016. Swiss medical weekly, 146 pp. w14350. Peer-reviewed.
Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Wojtowicz A., Bibert S., Beckmann S., Mueller N.J., Binet I. et al., 2016. PloS one, 11 (10) pp. e0164443. Peer-reviewed.
 
PTX3 Polymorphisms and Invasive Mold Infections After Solid Organ Transplant.
Wójtowicz A., Lecompte T.D., Bibert S., Manuel O., Rüeger S., Berger C., Boggian K., Cusini A., Garzoni C., Hirsch H. et al., 2015/08/15. Clinical infectious diseases, 61 (4) pp. 619-622. Peer-reviewed.
 
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.
Wang H., El Maadidi S., Fischer J., Grabski E., Dickhöfer S., Klimosch S., Flannery S.M., Filomena A., Wolz O.O., Schneiderhan-Marra N. et al., 2015. Hepatology (baltimore, Md.), 62 (5) pp. 1375-1387. Peer-reviewed.
 
Acute schistosomiasis: a risk underestimated by travelers and a diagnosis frequently missed by general practitioners-a cluster analysis of 42 travelers.
Rochat L., Bizzini A., Senn N., Bochud P.Y., Genton B., de Vallière S., 2015. Journal of Travel Medicine, 22 (3) pp. 168-173. Peer-reviewed.
 
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.
Terczyńska-Dyla E., Bibert S., Duong F.H., Krol I., Jørgensen S., Collinet E., Kutalik Z., Aubert V., Cerny A., Kaiser L. et al., 2015..
 
Host genetics of invasive Aspergillus and Candida infections.
Wójtowicz A., Bochud P.Y., 2015. Seminars in Immunopathology, 37 (2) pp. 173-186. Peer-reviewed.
IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation.
Wójtowicz A., Gresnigt M.S., Lecompte T., Bibert S., Manuel O., Joosten L.A., Rüeger S., Berger C., Boggian K., Cusini A. et al., 2015. Journal of Infectious Diseases, 211 (10) pp. 1646-1657. Peer-reviewed.
 
Impact of common risk factors of fibrosis progression in chronic hepatitis C.
Rüeger S., Bochud P.Y., Dufour J.F., Müllhaupt B., Semela D., Heim M.H., Moradpour D., Cerny A., Malinverni R., Booth D.R. et al., 2015. Gut, 64 (10) pp. 1605-1615. Peer-reviewed.
Influence of IFNL3/4 Polymorphisms on the Incidence of Cytomegalovirus Infection After Solid-Organ Transplantation.
Manuel O., Wójtowicz A., Bibert S., Mueller N.J., van Delden C., Hirsch H.H., Steiger J., Stern M., Egli A., Garzoni C. et al., 2015. Journal of Infectious Diseases, 211 (6) pp. 906-914.
Reply to Cunha et al.
Wójtowicz A., Lecompte T.D., Bibert S., Manuel O., Rüeger S., Berger C., Boggian K., Cusini A., Garzoni C., Khanna N. et al., 2015. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 61 (12) pp. 1894-1895. Peer-reviewed.
Schistosomiase aiguë au retour de voyage. Enseignements tirés d'une cohorte de 42 voyageurs exposés [Acute schistosomiasis: lessons learned from a cohort of 42 exposed travelers].
Rochat L., Bizzini A., Bochud P.Y., Senn N., De Vallière S., Genton B., 2015. Revue Médicale Suisse, 11 (473) pp. 1017-1022. Peer-reviewed.
 
The swiss transplant cohort study: lessons from the first 6 years.
Berger C., Bochud P.Y., Boggian K., Cusini A., Egli A., Garzoni C., Hirsch H.H., Hoffmann M., Khanna N., Manuel O. et al., 2015. Current Infectious Disease Reports, 17 (6) p. 486. Peer-reviewed.
Clinical significance of the CCR5delta32 allele in hepatitis C.
Morard I., Clément S., Calmy A., Mangia A., Cerny A., De Gottardi A., Gorgievski M., Heim M., Malinverni R., Moradpour D. et al., 2014. Plos One, 9 (9) pp. e106424. Peer-reviewed.
 
Host factors and genetic susceptibility to infections due to intracellular bacteria and fastidious organisms.
Asner S.A., Morré S.A., Bochud P.Y., Greub G., 2014. Clinical Microbiology and Infection, 20 (12) pp. 1246-1253.
 
Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia.
Kumar V., Cheng S.C., Johnson M.D., Smeekens S.P., Wojtowicz A., Giamarellos-Bourboulis E., Karjalainen J., Franke L., Withoff S., Plantinga T.S. et al., 2014. Nature Communications, 5 p. 4675. Peer-reviewed.
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index.
Hoggart C.J., Venturini G., Mangino M., Gomez F., Ascari G., Zhao J.H., Teumer A., Winkler T.W., Ternikova N., Luan J. et al., 2014. PLoS Genetics, 10 (7) pp. e1004508.
 
Polymorphisms in tumor necrosis factor-α increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*.
Wójtowicz A., Tissot F., Lamoth F., Orasch C., Eggimann P., Siegemund M., Zimmerli S., Flueckiger U.M., Bille J., Calandra T. et al., 2014. Critical Care Medicine, 42 (4) pp. e304-e308. Peer-reviewed.
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes
Terczyńska-Dyla E., Bibert S., Duong F.H., Krol I., Jørgensen S., Collinet E., Kutalik Z., Aubert V., Cerny A., Kaiser L. et al., 2014. Nature Communications, 5 p. 5699. Peer-reviewed.
 
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.
Bibert S., Wojtowicz A., Taffé P., Manuel O., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Kaiser L., Osthoff M. et al., 2014. Aids (london, England), 28 (13) pp. 1885-1889. Peer-reviewed.
 
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.
Covolo L., Bibert S., Donato F., Bochud P.Y., Lagging M., Negro F., Fattovich G., 2014. Alimentary Pharmacology and Therapeutics, 39 (3) pp. 322-330.
 
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.
Lange C.M., Bibert S., Dufour J.F., Cellerai C., Cerny A., Heim M.H., Kaiser L., Malinverni R., Müllhaupt B., Negro F. et al., 2013. Journal of Hepatology, 59 (3) pp. 504-509.
 
Differential impact of common risk factors of fibrosis progression in chronic hepatitis C
Rueger S., Bochud P.Y., Dufour J.F., Mullhaupt B., Semela D., Heim M.H., Moradpour D., Cerny A., Malinverni R., Kutalik Z. et al., 2013. pp. 1295A-1296A dans 64th Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Diseases, Hepatology.
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development.
Lange C.M., Miki D., Ochi H., Nischalke H.D., Bojunga J., Bibert S., Morikawa K., Gouttenoire J., Cerny A., Dufour J.F. et al., 2013. Plos One, 8 (5) pp. e64053. Peer-reviewed.
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.
Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., Duong F.H., Gerlach T., Malinverni R., Moradpour D. et al., 2013. Journal of Experimental Medicine, 210 (6) pp. 1109-1116. Peer-reviewed.
 
IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
Antaki N., Bibert S., Kebbewar K., Asaad F., Baroudi O., Alideeb S., Hadad M., Abboud D., Sabah H., Bochud P.Y. et al., 2013. Journal of Viral Hepatitis, 20 (1) pp. 59-64. Peer-reviewed.
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
Söderholm J., Waldenström J., Askarieh G., Pilli M., Bochud P.Y., Negro F., Pawlotsky J.M., Zeuzem S., Ferrari C., Norkrans G. et al., 2013. Plos One, 8 (2) pp. e56991.
 
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.
Pascarella S., Clément S., Dill M.T., Conzelmann S., Lagging M., Missale G., Neumann A.U., Pawlotsky J.M., Zeuzem S., Rubbia-Brandt L. et al., 2013. Liver International, 33 (1) pp. 94-103. Peer-reviewed.
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
Patin E., Kutalik Z., Guergnon J., Bibert S., Nalpas B., Jouanguy E., Munteanu M., Bousquet L., Argiro L., Halfon P. et al., 2012/11. Gastroenterology, 143 (5) pp. 1244-52.e1-12. Peer-reviewed.
 
A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease.
Renner Pascal, Roger Thierry, Bochud Pierre-Yves, Sprong Tom, Sweep Fred C.G.J., Bochud Murielle, Faust Saul N., Haralambous Elene, Betts Helen, Chanson Anne-Laure et al., 2012. Faseb Journal, 26 (2) pp. 907-916. Peer-reviewed.
A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C.
Lange C.M., Bibert S., Kutalik Z., Burgisser P., Cerny A., Dufour J.F., Geier A., Gerlach T.J., Heim M.H., Malinverni R. et al., 2012. Plos One, 7 (7) pp. e40159.
 
Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients.
Baur K., Mertens J.C., Schmitt J., Iwata R., Stieger B., Eloranta J.J., Frei P., Stickel F., Dill M.T., Seifert B. et al., 2012. Liver International, 32 (4) pp. 635-643. Peer-reviewed.
 
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.
Bochud P.Y., Bibert S., Kutalik Z., Patin E., Guergnon J., Nalpas B., Goossens N., Kuske L., Müllhaupt B., Gerlach T. et al., 2012. Hepatology, 55 (2) pp. 384-394.
 
IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.
Antaki N., Bibert S., Kebbewar K., Asaad F., Baroudi O., Alideeb S., Hadad M., Abboud D., Sabah H., Bochud P.Y. et al., 2012. Gut, 61 (11) pp. 1640-1641.
 
Role of CCR5 genetic polymorphisms in clinical and histological outcomes of hepatitis C
Morard I., Pascarella S., Calmy A., Mangia A., Clément S., Cerny A., Dufour J.F., Gorgievski M., Heim M., Malinverni R. et al., 2012. pp. 15S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange C.M., Kutalik Z., Morikawa K., Bibert S., Cerny A., Dollenmaier G., Dufour J.F., Gerlach T.J., Heim M.H., Malinverni R. et al., 2012. Hepatology, 55 (4) pp. 1038-1047. Peer-reviewed.
Species-Specific Recognition of Aspergillus fumigatus by Toll-like Receptor 1 and Toll-like Receptor 6.
Rubino I., Coste A., Le Roy D., Roger T., Jaton K., Boeckh M., Monod M., Latgé J.P., Calandra T., Bochud P.Y., 2012. Journal of Infectious Diseases, 205 (6) pp. 944-954. Peer-reviewed.
 
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
Guedj H., Guedj J., Negro F., Lagging M., Westin J., Bochud P.Y., Bibert S., Neumann A.U., for the DITTO-HCV study group, 2012. Journal of Viral Hepatitis, 19 (7) pp. 488-496.
 
A large-scale genetic validation study coupled with in vitro analyses reveal a role for vitamin Dsignaling in the pathogenesis and response to treatment of hepatitis C virus infection
Lange C.M., Bibert S., Kutalik Z., Morikawa K., Cerny A., Dufour J.F., Gerlach T.J., Heim M.H., Malinverni R., Muellhaupt B. et al., 2011. pp. S537 dans 46th Annual Meeting of the European Association for the Study of the Liver (EASL), Journal of Hepatology. Peer-reviewed.
 
Elevated serum f erritin is an independent predictor of severe liver fibrosis, steatosis, and treatment failure in chronic hepatitis C
Lange C.M., Kutalik Z., Morikawa K., Bibert S., Cerny A., Dufour J.F., Gerlach T.J., Heim M.H., Malinverni R., Müllhaupt B. et al., 2011. pp. 17S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society for Visceral Surgery, Swiss Association for the Study of the Liver, Swiss Medical Weekly. Peer-reviewed.
 
IL28B alleles associated with poor HCV clearance are protective against liver necroinflammatory activity and fibrosis progression in patients infected with non-1 HCV genotypes
Bochud P.Y., Bibert S., Kutalik Z., Patin E., Guergnon J., Nalpas B., Goossens N., Kuske L., Mullhaupt B., Gerlach T. et al., 2011. pp. 404A dans 62nd Annual Meeting of the American Association for the Study of Liver Diseases, Hepatology. Peer-reviewed.
 
IL28B polymorphisms leading to poor response to treatment are associated with low necroinflammatory activity and slow fibrosis progression in HCV genotype non-1-infected patients
Bochud P.Y., Bibert S., Kutalik Z., Goossens N., Muellhaupt B..., Gerlach T..., Heim M., Moradpour D., Cerny A., Malinverni R. et al., 2011. pp. S539 dans 46th Annual Meeting of the European Association for the Study of the Liver (EASL), Journal of Hepatology. Peer-reviewed.
 
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Bochud P.Y., Bibert S., Negro F., Haagmans B., Soulier A., Ferrari C., Missale G., Zeuzem S., Pawlotsky J.M., Schalm S. et al., 2011. Journal of Hepatology, 55 (5) pp. 980-988.
 
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G., Covolo L., Bibert S., Askarieh G., Lagging M., Clément S., Malerba G., Pasino M., Guido M., Puoti M. et al., 2011. Alimentary Pharmacology and Therapeutics, 33 (10) pp. 1162-1172.
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
Suppiah V., Gaudieri S., Armstrong N.J., O'Connor K.S., Berg T., Weltman M., Abate M.L., Spengler U., Bassendine M., Dore G.J. et al., 2011. Plos Medicine, 8 (9) pp. e1001092.
Immunogenetics of invasive aspergillosis.
Lamoth F., Rubino I., Bochud P.Y., 2011. Medical Mycology, 49 (Suppl. 1) pp. S125-S136.
 
Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic.
Boillat Blanco N., Probst A., Waeltu V., Giulieri S., Bernasconi E., Calmy A., Elzi L., Rauch A., Weber R., Bertisch B. et al., 2011. Journal of Acquired Immune Deficiency Syndromes, 58 (5) pp. 472-474.
 
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Lange C.M., Moradpour D., Doehring A., Lehr H.A., Müllhaupt B., Bibert S., Bochud P.Y., Antonino A.T., Pascual M., Farnik H. et al., 2011. Journal of Hepatology, 55 (2) pp. 322-327.
 
Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C.
Dill M.T., Duong F.H., Vogt J.E., Bibert S., Bochud P.Y., Terracciano L., Papassotiropoulos A., Roth V., Heim M.H., 2011. Gastroenterology, 140 (3) pp. 1021-1031.e10.
 
Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions
Fattovich G., Covolo L., Bibert S., Askarieh G., Lagging M., Clement S., Malerba G., Pasino M., Guido M., Puoti M. et al., 2011. pp. S87-8 dans Annual Meeting of the A.I.S.F. - Italian Association for the Study of the Liver, Digestive and Liver Disease. Peer-reviewed.
Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms.
Lagging M., Askarieh G., Negro F., Bibert S., Söderholm J., Westin J., Lindh M., Romero A., Missale G., Ferrari C. et al., 2011. Plos One, 6 (2) pp. e17232.
Role of hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis.
Probst Arnold, Dang Thanh, Bochud Murielle, Egger Matthias, Negro Francesco, Bochud Pierre-Yves, 2011. p. 42 dans Cardiovascular and Metabolic Disorders, FBM Research Day, January 27, 2011, FBM Research Day, Université de Lausanne, Faculté de biologie et de médecine.
 
Role of hepatitis C virus genotype 3 in liver fibrosis progression: a systematic review and meta-analysis.
Probst Arnold, Dang Thanh, Bochud Murielle, Egger Matthias, Negro Francesco, Bochud Pierre-Yves, 2011. Journal of Viral Hepatitis, 18 (11) pp. 745-759. Peer-reviewed.
 
The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C.
Iwata R., Stieger B., Mertens J.C., Müller T., Baur K., Frei P., Braun J., Vergopoulos A., Martin I.V., Schmitt J. et al., 2011. Journal of Viral Hepatitis, 18 (11) pp. 768-778.
 
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis.
Cai Tao, Dufour Jean-François, Muellhaupt Beat, Gerlach Tilman, Heim Markus, Moradpour Darius, Cerny Andreas, Malinverni Raffaele, Kaddai Vincent, Bochud Murielle et al., 2011. Journal of Hepatology, 55 (3) pp. 529-535. Peer-reviewed.
 
Genetic Polymorphisms and Susceptibility to Fungal Infections
Lamoth F., Bochud P.Y., Boeckh M., 2010. Journal of Invasive Fungal Infections, 4 (3) pp. 104-114. Peer-reviewed.
 
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J. et al., 2010. Gastroenterology, 138 (4) pp. 1338-45, 1345.e1-7. Peer-reviewed.
IFN stimulated gene expression in the liver is a better predictor of treatment response in chronic hepatitis c than the IL28b (IFN lambda 3) genotype
Dill M.T., Duong F.H.T., Vogt J.E., Bibert S., Bochud P.-Y., Terracciano L., Papassotiropoulos A., Roth V., Heim M.H., 2010. p. 461 dans 45th Annual Meeting of the European Association for the Study of Liver, Journal of Hepatology. Peer-reviewed.
 
IFN Stimulated Gene Expression in the Liver is a Better Predictor of Treatment Response in Chronic Hepatitis C than the IL28B (IFN lambda 3) Genotype
Dill Michael T., Duong Francois H. T., Vogt Julia E., Bibert Stephanie, Bochud Pierre-Yves, Terracciano Luigi, Papassotiropoulos Andreas, Roth Volker, Heim Markus H., 2010. pp. 4S dans Annual meeting of the Swiss Society of Gastroenterology, Swiss Society for Visceral, Surgery Swiss Association for the Study of the Liver, Swiss Association of Clinical Nutrition, Swiss Medical Weekly. Peer-reviewed.
IL28B polymorphism is significantly correlated with ifn anti-viral effectiveness already on first day of pegylated interferon-alpha and ribavirin therapy of chronic HCV infection
Neumann A., Bibert S., Haagmans B., Soulier A., Negro F., Lagging M., Ferrari C., Zeuzem S., Pawlotsky J.-M., Schalm S. et al., 2010. p. 468 dans 45th Annual Meeting of the European Association for the Study of Liver, Journal of Hepatology. Peer-reviewed.
 
Ip-10 Is Associated With Il28b Variation And Predicts The First Phase Decline Of Hcv Rna And Outcome Of Therapy In Chronic Hepatitis C
Lagging M., Askarieh G., Bochud P.Y., Bibert S., Negro F., Missale G., Ferrari C., Neumann A. U., Pawlotsky J.-M., Haagmans B. L. et al., 2010. pp. 766A dans 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Hepatology. Peer-reviewed.
 
The recent breakthroughs in the understanding of host genomics in hepatitis C.
Rauch Andri, Rohrbach Janine, Bochud Pierre-Yves, 2010. European Journal of Clinical Investigation, 40 (10) pp. 950-959.
A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation.
Bochud P.Y., Calandra T., 2009. Clinical Infectious Diseases, 49 (5) pp. 733-735.
 
Aspergillose invasive : perspectives en infectiologie préventive [Preventing invasive aspergillosis in hematopoietic stem cells transplant recipients.]
Lamoth F., Bochud P.Y., 2009. Médecine Sciences : M/S, 25 (8-9) pp. 669-672. Peer-reviewed.
 
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.
Bochud P.Y., Cai T., Overbeck K., Bochud M., Dufour J.F., Müllhaupt B., Borovicka J., Heim M., Moradpour D., Cerny A. et al., 2009. Journal of Hepatology, 51 (4) pp. 655-666. Peer-reviewed.
 
Genotype 3 is associated with rapid histological progression in chronic HCV infection
Bochud Pierre-Yves, Overbeck Kathrin, Bochud Murielle, Rickenbach Martin, Dufour Jean-François, Muellhaupt B., Borovicka Jan, Heim Markus, Moradpour Darius, Cerny Andreas et al., 2009. pp. 35S dans Joint annual congress of the Swiss Society for Allergology and Immunology and Swiss Society for Infectious Diseases, Geneva, March 19/20, 2009, Swiss Medical Weekly.
 
Host genetic determinants of spontaneous hepatitis C clearance
Rauch Andri, Gaudieri Silvana, Thio Chloe, Bochud Pierre-Yves, 2009. Pharmacogenomics, 10 (11) pp. 1819-1837. Peer-reviewed.
Maladies infectieuses [Infectious diseases]
Chapuis-Taillard C., de Vallière S., Bochud P.Y., 2009. Revue Médicale Suisse, 5 (185) pp. 29-34.
Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy.
Bochud P.Y., Sinsimer D., Aderem A., Siddiqui M.R., Saunderson P., Britton S., Abraham I., Tadesse Argaw A., Janer M., Hawn T.R. et al., 2009. European Journal of Clinical Microbiology & Infectious Diseases, 28 (9) pp. 1055-1065. Peer-reviewed.
Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.
Pine Samuel O., McElrath M. Juliana , Bochud Pierre-Yves, 2009. AIDS, 23 (18) pp. 2387-2395. Peer-reviewed.
 
Toll-like Receptor 4 Polymorphisms and Aspergillosis Reply
Bochud Pierre-Yves, Marr Kieren A., Boeckh Michael, 2009. New England Journal of Medicine, 360 (6) pp. 635-636. Peer-reviewed.
 
Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy.
Bochud P.Y., Hawn T.R., Siddiqui M.R., Saunderson P., Britton S., Abraham I., Argaw A.T., Janer M., Zhao L.P., Kaplan G. et al., 2008. Journal of Infectious Diseases, 197 (2) pp. 253-261. Peer-reviewed.
 
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.
Bochud P.Y., Chien J.W., Marr K.A., Leisenring W.M., Upton A., Janer M., Rodrigues S.D., Li S., Hansen J.A., Zhao L.P. et al., 2008. New England Journal of Medicine, 359 (17) pp. 1766-1777. Peer-reviewed.
Innate immunogenetics: a tool for exploring new frontiers of host defence.
Bochud P.Y., Bochud M., Telenti A., Calandra T., 2007. Lancet Infectious Diseases, 7 (8) pp. 531-542. Peer-reviewed.
 
Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection.
Bochud P.Y., Magaret A.S., Koelle D.M., Aderem A., Wald A., 2007. Journal of Infectious Diseases, 196 (4) pp. 505-509. Peer-reviewed.
 
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection.
Bochud P.Y., Hersberger M., Taffé P., Bochud M., Stein C.M., Rodrigues S.D., Calandra T., Francioli P., Telenti A., Speck R.F. et al., 2007. AIDS, 21 (4) pp. 441-446. Peer-reviewed.
 
Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review
Bochud P. Y., Bonten M., Marchetti O., Calandra T., 2004/11. Critical Care Medicine, 32 (11 Suppl) pp. S495-512.
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Erard V., Lamy O., Bochud P.Y., Bille J., Cometta A., Calandra T., 2004/02. European Journal of Clinical Microbiology & Infectious Diseases, 23 (2) pp. 82-88. Peer-reviewed.
 
Anti-cytokine therapies in patients with severe sepsis and septic shock.
Bochud P.Y., Glauser M.P., Calandra T., 2003. pp. 381-408 dans Kotb M., Clandra T. (eds.) Cytokines and Chemokines in Infectious Diseases Handbook, Humana Press.
 
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.
Bochud P.Y., Hawn T.R., Aderem A., 2003. Journal of Immunology, 170 (7) pp. 3451-3454. Peer-reviewed.
 
Pathogenesis of sepsis: new concepts and implications for future treatment.
Bochud P.Y., Calandra T., 2003. BMJ (Clinical research ed.), 326 (7383) pp. 262-6.
 
Cytokines in septic shock.
Calandra T., Bochud P.Y., Heumann D., 2002. Current clinical topics in infectious diseases, 22 pp. 1-23.
 
Empiric antimicrobial therapy for patients with severe sepsis and septic shock
Bochud P.Y., Glauser M.P., Carlet J., Calandra T., 2002. pp. 539-558 dans Vincent J.L., Carlet J., Opal S. (eds.) The Sepsis Text chap. 5, Boston : Kluwer Academic Publishers.
 
Empirical antibiotic therapy for patients with severe sepsis and septic shock.
Bochud P.Y., Glauser M.P., Carlet J., Calandra T., 2002. pp. 539-558 dans Vincent J.L., Carlet J., Opal S.M. (eds.) The Sepsis Text chap. 31, Kluwer Academic Pubishers.
 
Stratégies antimicrobiennes [Antimicrobial strategies]
Bochud P.Y., Praz G., 2002. pp. 106-135 dans Charbonneau P., Praz G., Glauser M.P. (eds.) Pathologies infectieuses en réanimation, Elsevier.
 
Community-acquired pneumonia. A prospective outpatient study.
Bochud P.Y., Moser F., Erard P., Verdon F., Studer J.P., Villard G., Cosendai A., Cotting M., Heim F., Tissot J. et al., 2001/03. Medicine, 80 (2) pp. 75-87.
 
Antibiotics in sepsis
Bochud P. Y., Glauser M. P., Calandra T., 2001. Intensive Care Medicine, 27 Suppl 1 pp. S33-48.
 
Batériémie à Citrobacter koseri comme présentation initiale d'un cancer colique [Citrobacter koseri bacteremia as initial presentation of a colic cancer]
Chossis I., Bochud P.Y., Bille J., Lamy O., 2001. Swiss Medical Forum = Forum Médical Suisse, 1 (25) pp. 662-663.
 
Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media.
Bochud P.Y., Calandra T., Moreillon P., Baumgartner J.D., Yersin B., 2001. European Journal of Clinical Microbiology and Infectious Diseases, 20 (2) pp. 136-137.
 
Les endocardites dues aux germes du groupe HACEK. A propos d'un cas d'endocardite native a Kingella kingae. [Endocarditis due to HACEK bacteria. A case report of endocarditis due to Kingella kingae]
Lepori M., Bochud P. Y., Owlya R., Broccard A., Schaller M. D., 2001. Revue Médicale de la Suisse Romande, 121 (1) pp. 47-50.
 
Prise en charge de la pneumonie communautaire [Management of community acquired pneumonia]
Bochud P.Y., Francioli P., Lew D., 2001. Médecine et Hygiène, 59 (2341) pp. 765-770.
 
Epidemiologie et prise en charge de l'infarctus du myocarde a l'Hopital cantonal de Fribourg en 1995. [Epidemiology and care of myocardial infarct at the Fribourg Canton Hospital 1995]
Bochud P. Y., Stauffer J. C., Mottet J. J., Regamey C., 1998/03. Schweizerische Medizinische Wochenschrift, 128 (10) pp. 363-73.
 
Virulent infections due to alpha-haemolytic streptococci in cancer patients and their management
Bochud P.Y., Cometta A., Francioli P., 1997. Current Opinion in Infectious Diseases, 10 (6) pp. 422-430. Peer-reviewed.
 
Reply
Bochud P.- Y., Eggiman P., Calandra T., Van Melle G., Saghafi L., Francioli P., 1995/02/01. Clinical Infectious Diseases, 20 (2) pp. 470-470.
 
Bacteremia Due to Oral Viridans Streptococci in Neutropenic Patients with Cancer: Cytostatics Are a More Important Risk Factor than Antibacterial Prophylaxis - Reply
Bochud P.Y., Eggimann P., Calandra T., Vanmelle G., Saghafi L., Francioli P., 1995. Clinical Infectious Diseases, 20 (2) p. 470.
 
Bacteremia due to viridans streptococci in neutropenic patients: a review
Bochud P. Y., Calandra T., Francioli P., 1994/09. American Journal of Medicine, 97 (3) pp. 256-64.
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.
Bochud P.Y., Eggiman P., Calandra T., Van Melle G., Saghafi L., Francioli P., 1994/01. Clinical Infectious Diseases, 18 (1) pp. 25-31. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University